Patients with high levels of Aβ42 in the peripheral blood have an increased risk of dementia after 5 years; in addition, peripheral blood levels of tau protein are higher in AD patients and significantly associated with future cognitive impairment (Fiandaca et al., 2015; McDade and Bateman, 2017). Here, MAPT is linked to Alzheimer disease.